Rhumbline Advisers Belite Bio, Inc Put Options Transaction History
Rhumbline Advisers
- $109 Billion
- Q4 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding BLTE
# of Institutions
20Shares Held
80.3KCall Options Held
0Put Options Held
0-
State Street Corp Boston, MA20.1KShares$1.16 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC13.5KShares$773,8360.0% of portfolio
-
Marshall Wace, LLP London, X08.49KShares$488,1990.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.7KShares$385,4510.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il6.46KShares$371,6430.0% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $1.43B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...